Absci Reports Q4 and Full Year 2025 Financial Results and Major Business Updates

Key Highlights and Potential Price-Moving Developments

• Clinical Milestones: Successfully dosed first three cohorts in the SAD portion of Phase 1/2a HEADLINE trial for ABS-201, with favorable emerging safety data. ABS-201 is now Absci’s lead clinical candidate for androgenetic alopecia (AGA).
• Pipeline Expansion: ABS-201 also being developed for endometriosis, with a Phase 2 trial planned for Q4 2026. The company is targeting a significant unmet need, with no approved disease-modifying therapies for endometriosis.
• Proof-of-Concept Timelines: Interim proof-of-concept data for ABS-201 in AGA expected in H2 2026, and for endometriosis in H2 2027. Full proof-of-concept data for AGA anticipated in early 2027.
• Innovative AI Drug Design Platform: Released a manuscript on Origin-1, Absci’s generative AI platform, which can design full-length monoclonal antibodies against “zero-prior” epitopes. This is a potential industry first and could dramatically accelerate antibody discovery.
• Leadership Addition: Appointed Dr. Ransi Somaratne (ex-Vertex, BioMarin, Amgen) as Chief Medical Officer to spearhead clinical strategy and execution.
• Financial Position: Cash, cash equivalents, and marketable securities of \$144.3 million as of December 31, 2025, expected to fund operations into the first half of 2028.
• Strategic Partnerships: Absci anticipates signing one or more new drug creation partnerships in 2026, including with a Large Pharma company, which could be highly significant for future growth and validation.
• Other Pipeline Developments: Ongoing partnering and outlicensing efforts for ABS-101 (anti-TL1A antibody), and progress in immuno-oncology (ABS-301) and anti-HER2 (ABS-501) programs, with positive preclinical data and novel antibody leads identified.

Detailed Business Updates

ABS-201 (Anti-PRLR Antibody) for Androgenetic Alopecia

Absci’s lead program, ABS-201, an anti-PRLR antibody, is under Phase 1/2a clinical evaluation for the treatment of androgenetic alopecia (AGA), commonly known as male and female pattern hair loss. The company has successfully dosed the first three cohorts in the single ascending dose (SAD) portion of the ongoing trial, with the candidate well-tolerated and showing favorable emerging safety data.

Notably, human ex vivo data revealed that ABS-201 can stimulate hair growth by regenerating the follicle stem cell niche and modulating key growth pathways, including significant inhibition of the PRLR signaling pathway (STAT5 phosphorylation). This was associated with a prolongation of the anagen phase and restoration of hair growth, indicating strong potential for durable and convenient hair regrowth therapy.

Absci is targeting the reporting of preliminary safety, tolerability, and pharmacokinetic data in H1 2026, interim proof-of-concept data in H2 2026, and full proof-of-concept data in early 2027.

ABS-201 for Endometriosis

ABS-201 is also being developed for endometriosis, a prevalent condition with an estimated 9 million women affected in the U.S. alone and no current FDA-approved disease-modifying therapies. This indication represents a major expansion opportunity and a large, underserved market.

Unlike existing treatments, ABS-201 offers a novel, non-sex steroid hormone mechanism, with the potential to be disease-modifying, impact both pain and lesion growth, and provide an improved safety profile. Absci plans to initiate a Phase 2 clinical trial in Q4 2026, with potential proof-of-concept data in H2 2027.

Origin-1 AI Platform and Pipeline Expansion

A major technological milestone, Absci released data on its Origin-1 AI platform. This platform is capable of de novo design of full-length monoclonal antibodies against “zero-prior” epitopes (targets for which there is no previously known binding protein). Unlike traditional methods that require screening thousands of candidates, Origin-1 generated potential leads with less than one hundred designs per target, demonstrating atomically accurate complex structures and functional activity.

This breakthrough could significantly disrupt antibody discovery, attract industry partnerships, and enhance Absci’s pipeline acceleration.

Additional Program and Partnership Updates

• ABS-101 (anti-TL1A antibody): Partnership and outlicensing discussions are ongoing, with further indication expansion opportunities being explored.
• ABS-301 (Immuno-oncology): Fully human antibody designed for a novel target, with preclinical data supporting potential in squamous cell carcinomas and other cancers.
• ABS-501 (anti-HER2): Using AI, Absci identified antibody leads with novel epitope interactions, high affinity, activity against trastuzumab-resistant tumors, and strong developability profiles.
• Drug Creation Partnerships: Progress is being made on existing partnerships, and Absci expects at least one new partnership with a large pharmaceutical company in 2026, which could be a major validation of its technology and pipeline.

Financial Summary

• Q4 2025 revenue was \$0.7 million, flat year-over-year. Full year 2025 revenue was \$2.8 million, down from \$4.5 million in 2024, reflecting timing of partner program revenue recognition.
• R&D expenses increased to \$25.3 million in Q4 2025 (from \$18.4 million in Q4 2024), and \$81.4 million for the full year (up from \$63.9 million), driven by advancement of internal programs, preclinical and clinical development for ABS-101 and ABS-201.
• Selling, general, and administrative expenses were \$8.6 million for Q4 2025 and \$35.1 million for the full year, both slightly decreased due to reduced personnel costs.
• Net loss for Q4 2025 was \$29.6 million (vs. \$29.0 million in Q4 2024), with a full year net loss of \$115.2 million (vs. \$103.1 million in 2024).
• Notably, the company recorded a \$5.1 million gain on settlement of contingent consideration in Q4 2025, resulting in \$8.7 million in unrestricted cash.
• Cash, cash equivalents, and marketable securities totaled \$144.3 million as of December 31, 2025 (down from \$152.5 million at September 30, 2025). Absci believes this is sufficient to fund operations into the first half of 2028.

Leadership Update

Dr. Ransi Somaratne, M.D., FACC, MBA, joins as Chief Medical Officer. Dr. Somaratne brings significant clinical development leadership, most recently from Vertex Pharmaceuticals, and previously BioMarin and Amgen, to drive Absci’s clinical pipeline execution and strategy.

Investor and Shareholder Considerations

• Clinical Progress: The successful dosing and favorable safety data for ABS-201, as well as the planned proof-of-concept milestones, represent potential value inflection points in 2026-2027.
• AI Platform Validation: The Origin-1 platform could attract significant interest from partners and investors, as it represents a potential step-change in biologics discovery.
• Cash Runway: With \$144.3 million in cash and equivalents, Absci is well-capitalized for the near- to medium-term, reducing financing risk.
• Upcoming Partnerships: Anticipated new large pharma partnerships in 2026 could positively impact the share price, adding external validation and non-dilutive capital.
• Large Market Opportunities: Both AGA and endometriosis are large, underserved markets. Success in these areas could significantly re-rate the company’s valuation.

Conference Call and Webcast

Absci will host a conference call to discuss these results on March 24, 2026, at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time), accessible at investors.absci.com. The webcast will be available for replay for at least 90 days.

About Absci

Absci is a clinical-stage biopharmaceutical company leveraging generative AI and synthetic biology to accelerate biologics drug discovery. The company’s Integrated Drug Creation™ platform combines AI, wet-lab validation, and a data engine to create innovative therapeutics, with an expanding pipeline and collaborations with leading pharma, biotech, and academic institutions.

Disclaimer: This article is based on Absci’s Q4 and full year 2025 financial and business update press release. Forward-looking statements are subject to risks and uncertainties, and actual results may differ materially from those expressed. Investors should review Absci’s filings with the SEC and consult their financial advisors before making investment decisions. This article is for informational purposes only and does not constitute investment advice.

View Absci Corp Historical chart here